{"nctId":"NCT04674761","briefTitle":"Efficacy and Safety of Odevixibat in Patients With Alagille Syndrome","startDateStruct":{"date":"2021-03-19","type":"ACTUAL"},"conditions":["Alagille Syndrome"],"count":52,"armGroups":[{"label":"Odevixibat (A4250)","type":"EXPERIMENTAL","interventionNames":["Drug: Odevixibat"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Odevixibat","otherNames":["A4250"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Genetically confirmed diagnosis of Alagille syndrome\n* History of significant pruritus as measured by the Albireo Observer or Patient Reported Outcome instrument\n* Elevated serum bile acid level\n\nKey Exclusion Criteria:\n\n* History or ongoing presence of other types of liver disease (eg. biliary atresia, progressive familial intrahepatic cholestasis, hepatocellular carcinoma)\n* History of liver transplant, or a liver transplant is planned within 6 months of randomization\n* ALT \\>10× upper limit of normal (ULN) at screening\n* Total bilirubin \\>15 × ULN at screening\n* Patient suffers from uncontrolled, recalcitrant pruritic condition other than Alagille syndrome","healthyVolunteers":false,"sex":"ALL","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Scratching Score","description":"Change from baseline in average AM (measured after waking up) and PM (measured before bedtime) scratching score to Month 6 as measured by the Albireo Observer-Reported Outcome (ObsRO) Instrument. The ObsRO instrument was used to assess severity of observed scratching twice a day (AM and PM) with scores from 0 to 4 where 0 is no scratching and 4 is worst possible scratching.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.69","spread":"0.174"},{"groupId":"OG001","value":"-0.8","spread":"0.233"}]}]}]},{"type":"SECONDARY","title":"Serum Bile Acid Levels","description":"Change in serum bile acid levels (μmol/L) from baseline to average of week 20 and 24","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-90.35","spread":"21.336"},{"groupId":"OG001","value":"22.39","spread":"28.463"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":35},"commonTop":["Pyrexia","Diarrhoea","COVID-19","Abdominal pain","Upper respiratory tract infection"]}}}